SI-BONE to Present at the 23rd Annual Needham Growth Conference and the 39th Annual J.P. Morgan Healthcare Conference
SI-BONE, Inc. (Nasdaq: SIBN) announced participation in two major healthcare conferences: the 23rd Annual Needham Growth Conference and the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SI-BONE, Inc. (Nasdaq: SIBN) announced participation in two major healthcare conferences: the 23rd Annual Needham Growth Conference and the 39th Annual J.P. Morgan Healthcare Conference. Management will engage in a Fireside Chat on January 11, 2021, at 2:45 p.m. ET and will present on January 14, 2021, at 2:50 p.m. ET. Both events will be accessible via live and archived webcasts on the company's website. SI-BONE specializes in minimally invasive surgery for sacropelvic disorders, with its iFuse Implant System backed by extensive clinical studies.
Details
News Market Reaction – SIBN
The recorded move for SIBN in the trading session of this news was +2.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA CLARA, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming 23rd Annual Needham Growth Conference and the 39th Annual J.P. Morgan Healthcare Conference.
For the Needham Growth Conference, SI-BONE’s management is scheduled for a Fireside Chat on Monday, January 11, 2021 at 2:45 p.m. Eastern Time / 11:45 a.m. Pacific Time.
For the J.P. Morgan Healthcare Conference, SI-BONE’s management is scheduled to present on Thursday, January 14, 2021 at 2:50 p.m. Eastern Time / 11:50 a.m. Pacific Time.
Interested parties may access a live and archived webcast of the events on the “Investors” section of the company’s website at: www.si-bone.com.
About SI-BONE
SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in
The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. In addition, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.
SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2020 SI-BONE, Inc. All Rights Reserved. 12172020
Investor Contact:
Matt Bacso, CFA
investors@SI-BONE.com
Media Contact:
Joe Powers
jpowers@si-bone.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.